Gilead’s HCV Drug Faces India Patent Challenge Over Pricing
Although Gilead Sciences Inc.’s sofosbuvir could make history as the first interferon-free treatment to be approved for hepatitis C, it may face generic competition in India soon after it hits the market because it isn’t innovative enough, according to some advocacy groups.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter